Ranexa MERLIN study complete
This article was originally published in Pharmaceutical Approvals Monthly
CV Therapeutics expects top-line data from its MERLIN study of Ranexa (ranolazine) in the first quarter of 2007. The firm announced Sept. 26 that MERLIN (Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary Syndromes) is complete and will soon move to the close-out phase. MERLIN was designed under a special protocol assessment with FDA; the agreement stipulates that if the primary endpoint of time to first occurrence of any element of a composite endpoint is met, Ranexa could potentially be approved for treatment of ACS and secondary prevention. CVT has also said it believes MERLIN would support a labeling expansion to first-line angina (1Pharmaceutical Approvals Monthly May 2005, p. 10)...
You may also be interested in...
A mean weekly reduction of 0.4 angina attacks seen in the ERICA study with CV Therapeutics' Ranexa (ranolazine) is adequate for approval, the company said, despite being less than half the expected decrease
ACIP defers vote on who should be inoculated first until it has data on a specific product, but vaccine acceptance among different groups could be weighed as factor in setting distribution priorities, committee members suggest.
The Personal Care Products Council’s Francine Lamoriello, EVP of global strategies, discusses shortcomings of a proposed animal-testing exemption for imported general cosmetics under a key implementing regulation drafted for China’s new cosmetics oversight framework.